ROSEN, A Top Ranked Law Firm, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPHNewsfile Corp • 05/16/22
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR CongressBusiness Wire • 05/16/22
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors With Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action - AUPHPRNewsWire • 05/15/22
ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - AUPHNewsfile Corp • 05/14/22
INVESTOR DEADLINE: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AUPHBusiness Wire • 05/13/22
Shareholder Action Reminder: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 05/11/22
Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22
AUPH NOTICE: ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPHNewsfile Corp • 05/09/22
Shareholder Action Alert: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 05/09/22
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022Business Wire • 05/06/22
AUPH LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Aurinia Pharmaceuticals Inc.Newsfile Corp • 05/04/22
Investor Action Alert: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 05/04/22
ROSEN, A TOP RANKED FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPHNewsfile Corp • 05/03/22
Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022Business Wire • 05/02/22
ROSEN, Leading Investor Counsel, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - AUPHNewsfile Corp • 05/02/22
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPHPRNewsWire • 04/30/22
Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/28/22
Investor Action Reminder: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 04/28/22
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPHNewsfile Corp • 04/27/22
AUPH Stock News: Robbins LLP Investigates Aurinia Pharmaceuticals Inc. (AUPH) on Behalf of ShareholdersBusiness Wire • 04/26/22
AUPH SHAREHOLDER ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPHNewsfile Corp • 04/25/22
INVESTOR ALERT: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AUPHPRNewsWire • 04/23/22
DEADLINE: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AUPHBusiness Wire • 04/22/22